Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality.
Ontology highlight
ABSTRACT: Recent randomized trials suggest that interleukin-6 inhibitors reduce mortality due to severe coronavirus disease 2019. Using a decision tree model, we found that tocilizumab is cost-effective with an estimated incremental cost-effectiveness ratio of $16 520 per quality-adjusted life year gained (95% credible interval, 10 760-51 530).
SUBMITTER: Sinha P
PROVIDER: S-EPMC8135952 | biostudies-literature |
REPOSITORIES: biostudies-literature
ACCESS DATA
